ZOLIMIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H12N2O2S
Molecular Weight	272.322
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)C1=CC=C(C=C1)C2=CN3C=CC=CC3=N2

InChI

InChIKey=VSLIUWLPFRVCDL-UHFFFAOYSA-N

InChI=1S/C14H12N2O2S/c1-19(17,18)12-7-5-11(6-8-12)13-10-16-9-3-2-4-14(16)15-13/h2-10H,1H3

HIDE SMILES / InChI

Molecular Formula	C14H12N2O2S
Molecular Weight	272.322
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.whocc.no/atc_ddd_index/?code=A02BX10 | http://www.dica33.it/SOLIMIDIN/?f=xuiqpzolqmfkpz | https://www.ncbi.nlm.nih.gov/pubmed/161649

Zolimidine, a derivate of imidazopyridine, has a gastroprotective effect. It is used in the treatment of peptic ulcer and gastro-oesophageal reflux disease.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Peptic ulcer 72 Sources: https://www.whocc.no/atc_ddd_index/?code=A02BX10 http://www.dica33.it/SOLIMIDIN/?f=xuiqpzolqmfkpz	Primary		Approved 8583	SOLIMIDIN Approved Use Unknown
Gastroesophageal reflux disease 68 Sources: https://www.whocc.no/atc_ddd_index/?code=A02BX10 http://www.dica33.it/SOLIMIDIN/?f=xuiqpzolqmfkpz	Primary		Approved 8583	SOLIMIDIN Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 59.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 1.0	yes [IC50 0.4565 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 15.0	yes [IC50 13.8029 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 19.0	yes [IC50 24.5454 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 7.0	yes [IC50 5.495 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/14652#section=WIPO-PATENTSCOPE Page: 64.0

PubMed

Title	Date	PubMed
Ethyl 8-(4-nitro-phen-yl)imidazo[1,2-a]pyridine-7-carboxyl-ate.	2010-11-24	21589555
6-Benzyl-3,4-dimeth-oxy-10-methyl-pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5(6H)-one.	2009-09-12	21577919

Patents

Sample Use Guides

In Vivo Use Guide

1200 mg/day

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:00:24 GMT 2025` Edited by `admin` on `Wed Apr 02 08:00:24 GMT 2025`
Record UNII	YCF001N8QB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOLIMIDIN

Preferred Name

English

ZOLIMIDINE

Official Name

English

ZOLIRIDINE

Common Name

English

Zolimidine [WHO-DD]

Common Name

English

zolimidine [INN]

Common Name

English

SOLIMIDINE

Common Name

English

ZOLIMIDINE [MI]

Common Name

English

ZOLIMIDINE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29701